Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629962 · ClinicalTrials.gov registry record · Phase 3
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
A Phase 3 study, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,285
- Enrollment target
NCT05629962 is a Phase 3 study that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 2,285 participants.
The verdict
NCT05629962, a Phase 3 study, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,285 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Interventions
- DRUG Placebo
- DRUG Bemnifosbuvir (BEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,285 participants |
| Start Date | 2022-11-25 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05629962
The ClinicalTrials.gov registry entry for NCT05629962 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05629962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05629962 about?
NCT05629962 is a clinical study titled "SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19". The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching place...
What is the current status of trial NCT05629962?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,285 participants. The study started on 2022-11-25. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT05629962?
The interventions under investigation include: Placebo (DRUG), Bemnifosbuvir (BEM) (DRUG).
Who is sponsoring clinical trial NCT05629962?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.